IGE Therapeutics Inc.

San Diego, CA

UEI
XF2MYFW5XPD5
CAGE
48E51
Primary NAICS
813920 Professional Organizations
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Asian-Pacific American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
11533 Spruce Run Dr, San Diego, CA 92131, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Broadly neutralizing(BN) pan-IGE supersite vaccine for allergic asthma R44AI126680 National Institute of Allergy and Infectious Diseases (NIH) $2,609,527
CTL for supertype natural IGE cytotoxic peptide (necp) to guard against allergic asthma R44AI122358 National Institute of Allergy and Infectious Diseases (NIH) $2,258,938
BI-functional therapeutics for allergy-bfta R43AI082770 National Institutes of Health $600,000
Targeting galectin-3 with novel drugs for treatment of eczema R43AI084348 National Institutes of Health $803,683

Quick answers

Is IGE Therapeutics Inc. registered in SAM.gov?

Yes. IGE Therapeutics Inc.'s SAM.gov registration is active through April 2, 2027.

What is IGE Therapeutics Inc.'s most recent federal award?

IGE Therapeutics Inc.'s most recent federal grant award is Broadly neutralizing(BN) pan-IGE supersite vaccine for allergic asthma (R44AI126680), from National Institute of Allergy and Infectious Diseases (NIH), on March 1, 2017.

On GovTribe

See IGE Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login